AN2 Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On September 1, 2023, the Company’s Board of Directors appointed Lucy Day, the Company’s current Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer effective as of September 1, 2023.
The Company has hired Annie Yoshiyama, previously Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., as its new Vice President, Finance and Corporate Controller.
Michael Nazak, Vice President, Corporate Controller and the prior Principal Accounting Officer, will depart the Company effective September 15, 2023.
Extracted from this filing and checked against the source text.
Lucy Day was appointed as Principal Accounting Officer at AN2 Therapeutics, Inc..
On September 1, 2023, the Company’s Board of Directors appointed Lucy Day, the Company’s current Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer effective as of September 1, 2023.View on SEC.gov
Annie Yoshiyama was appointed as Vice President, Finance and Corporate Controller at AN2 Therapeutics, Inc..
The Company has hired Annie Yoshiyama, previously Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., as its new Vice President, Finance and Corporate Controller.View on SEC.gov
Michael Nazak departed as Vice President, Corporate Controller at AN2 Therapeutics, Inc..
Michael Nazak, Vice President, Corporate Controller and the prior Principal Accounting Officer, will depart the Company effective September 15, 2023.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.